A combination of anti-VEGF antibody treatment and DAPT further regressed tumor growth (0.428 g) in animal models, suggesting that Notch inhibition could reduce anti-VEGF antibody resistance due to VM in lung cancer (Figure 6C). Here, VEGFA is linked to lung carcinoma.